Table 2.
Pooled prevalence estimations for LTBI by WHO regions.
| Studies (n) | Prevalence (%) | 95% CI | |
|---|---|---|---|
| Europe | |||
| All studies | 32 | 16.4 | 13.1–19.6 |
| Study quality (+++/++) | 25 | 16.3 | 12.6–20.1 |
| ≥139 participants | 20 | 13.9 | 10.1–17.7 |
| The Americas | |||
| All studies | 5 | 16.5 | 9.8–23.2 |
| Study quality (+++/++) | 3 | 19.3 | 1.6–36.9 |
| ≥139 participants | 4 | 14.9 | 7.8–22.0 |
| North America | 3 | 4.5 | 3.8–5.2 |
| Western Pacific | |||
| All studies | 9 | 4.8 | 3.0–6.6 |
| Study quality (+++/++) | 9 | 4.8 | 3.0–6.6 |
| ≥139 participants | 9 | 4.8 | 3.0–6.6 |
| Eastern Mediterranean | |||
| All studies | 11 | 19.4 | 13.0–25.7 |
| Study quality (+++/++) | 9 | 16.1 | 9.5–22.7 |
| ≥139 participants | 7 | 15.2 | 7.9–22.6 |
Study quality: +++ high, ++ moderate.